How to Qualify a Peptide CDMO: US Buyer Checklist

Shortlist a peptide CDMO only after it clears six evidence checks: molecule fit, transfer readiness, analytical control, scale history, quality documentation, and supply continuity. Our rule of thumb is simple: score candidates to 100 points, require at least 80 points, and reject any candidate with an unresolved quality, traceability, or subcontracting gap.

A large facility, a generic GMP certificate, or a high HPLC purity figure cannot answer the buyer’s real question: can this named site make, test, release, transfer, and reliably supply your peptide?

Use This Weighted Peptide CDMO Checklist

Start with one RFI package for every candidate. Ask each candidate for evidence against the same six sections, then score responses with CMC, QA, regulatory, and supply-chain owners present.

ICH quality-risk guidance supports this approach. It says the formality of risk management should reflect the decision’s uncertainty, importance, and complexity. ICH Q9(R1)

1. Molecule and Development-Stage Fit, 15 Points

Request:

• Comparable peptide work by sequence length, modification, cyclization, conjugation, disulfide pattern, salt form, and purification challenge.
• A stage-specific scope showing discovery, process development, clinical GMP, transfer, or commercial work.
• Names and addresses for the development, manufacturing, testing, packaging, storage, and release sites.
• A list of every subcontracted activity.

Red flags:

• “We manufacture all peptide types” without comparable technical evidence.
• A GMP campaign proposal for a route that still needs synthesis or impurity development.
• A proposal that names a commercial office but not the manufacturing site.

Owner: CMC lead.

Choose the partner for the next irreversible decision. A program that still needs a repeatable route and impurity strategy needs development capability. A mature process needs a receiving GMP site that can execute the transfer package. ICH Q11 supports building process knowledge and a control strategy through the drug-substance lifecycle.

For a stage-by-stage partner brief, use our peptide CDMO process-development guide.

2. Development Transfer Readiness, 15 Points

Request:

• A process map covering synthesis, cleavage, purification, isolation, drying, packaging, and storage.
• Critical quality attributes, or CQAs, which are the properties that must stay within limits.
• A method-transfer plan and a process-transfer plan.
• Comparability acceptance criteria agreed before transfer work starts.
• Change-control and deviation governance for the transfer.

Red flags:

• The site starts transfer work before defining what counts as comparable material.
• The proposed receiving site cannot perform a critical process or analytical step.
• The CDMO can name equipment but cannot explain the transfer protocol.

Owner: CMC lead and QA.

A transfer package must allow the receiving team to execute, investigate, and control the process. Ask for representative material, representative process conditions, and the exact analytical results that must match after transfer.

What Analytical and Impurity Evidence Should You Request?

Ask for a representative, lot-specific quality package before a site enters the shortlist. A product brochure cannot replace a batch record, current specification, or method status.

3. Analytical and Impurity Control, 20 Points

Request:

• A representative certificate of analysis with batch number, test methods, limits, and numerical results.
• Current specifications for identity, assay or content, purity, related substances, water, residual solvents, elemental impurities, and counterion where relevant.
• Method validation or phase-appropriate qualification status.
• Representative chromatograms and mass-spectrometry identity evidence.
• Stability protocol and data for the proposed packaging and storage conditions.
• An impurity-control rationale for starting materials, synthesis, purification, and storage.

Red flags:

• HPLC area purity is the only reported result.
• The COA omits methods, limits, or numerical results.
• The candidate cannot distinguish purity from peptide content.
• The site has no stability-indicating method plan.

Owner: Analytical development and QA.

For synthetic peptides, purity is a key CQA. Peptide-related impurities and non-peptide impurities can arise from starting materials, synthesis, degradation, reagents, solvents, and elemental sources. EMA peptide guidance identifies those risks directly.

Analytical procedures should be fit for their intended purpose, including release and stability use. ICH Q2(R2) provides the validation framework. For the buyer-side distinction between purity and usable content, read why peptide HPLC purity differs from content.

Can the Site Transfer and Scale Your Process Reliably?

Ask for history at a scale that resembles your program. A large reactor does not establish final API output, purification recovery, drying capacity, quality-release capacity, or campaign availability.

4. Scale History and Execution, 15 Points

Request:

• Comparable batch history by actual API output and development stage.
• Yield and purification-recovery trends at relevant scale.
• Evidence for purification, isolation, drying, packaging, and release-laboratory capacity.
• Planned engineering and GMP campaign dates.
• A summary of representative deviations and process learning.
• Equipment availability for the proposed campaign.

Red flags:

• Reactor volume replaces comparable batch history.
• A kilogram claim excludes purification recovery or release testing.
• Capacity evidence has no campaign timing or assigned equipment.

Owner: Technical operations and CMC.

A useful scale history follows the material through the whole process. It identifies what the site made, at which site, with which route, how much API it released, and which controls changed as output increased. That evidence is more useful than a generic “commercial scale” label.

For a clinical-to-commercial review, use our clinical peptide scale-up guide.

Which Quality Documents Should US Buyers Review?

Review the quality package before commercial terms. The package should show who controls the work, where the work occurs, how changes are approved, and how the sponsor can audit the site.

5. Quality, Audit, and Filing Documents, 20 Points

Request:

• Current GMP certificate for the exact site and activity.
• Quality-system overview, including deviation, CAPA, OOS, complaints, recall, and data-governance procedures.
• Inspection and enforcement history for the named manufacturing and testing sites.
• A sample quality agreement.
• Change-control categories, notification timelines, and approval rights.
• Product-specific DMF support and letter-of-authorization process, when the filing route needs one.
• A written subcontracting policy.

Red flags:

• A registration number is presented as FDA approval.
• A DMF is presented as FDA approval.
• The GMP certificate does not cover the proposed activity or site.
• The quality agreement lacks audit rights or subcontractor approval.

Owner: QA and regulatory affairs.

ICH Q7 says the contract giver should evaluate contract manufacturers, define GMP responsibilities in a written agreement, retain audit rights, and approve subcontracting arrangements. ICH Q7 contract controls

FDA also explains that establishment registration does not mean FDA has approved the product or verified the submitted information. FDA registration guidance A DMF is voluntary and is neither approved nor disapproved. FDA reviews it only when an application references it. FDA DMF guidance

Use FDA’s inspection database as part of diligence, but treat it as one source. FDA says the public database is not a complete record of every inspection. FDA inspection database

What Supply-Continuity Risks Belong in the Assessment?

Supply continuity belongs in the initial qualification. A qualified batch does not protect a program if a critical amino acid, resin, purification input, release method, cold-chain lane, or manufacturing slot fails later.

6. Supply Continuity and Logistics, 15 Points

Request:

• A map of critical starting materials and qualified alternate sources.
• Capacity reservation assumptions and lead-time plan.
• Inventory strategy for critical materials and released API.
• Packaging configuration, storage conditions, and route-specific shipment controls.
• Temperature-excursion response procedure.
• Change-notification terms for materials, equipment, methods, sites, and capacity.
• A second-source or recovery plan for commercial programs.

Red flags:

• “Cold chain available” without packaging, lane, and excursion details.
• One source for a critical input without a recovery plan.
• No notification terms for upstream material or manufacturing-site changes.

Owner: Supply chain and QA.

Put supply evidence beside quality evidence, not after contract signature. Our peptide API supply-chain checklist helps buyers add storage, shipment, and handoff controls to the qualification file.

Turn the Score into a Shortlist

Add the six scores after each RFI review. Keep the supporting documents, dates, site names, and unresolved questions beside the score.

A candidate that scores 85 points but hides a testing subcontractor does not qualify. A candidate that scores 78 points with strong evidence may stay in the evidence-request stage, but should not displace a candidate that cleared the complete checklist.

Audit the highest-scoring candidates before selection. The audit should test whether the process, laboratory, quality, and supply teams give the same answers as the RFI package. Then attach the final scorecard to the quality agreement and use it as the baseline for future changes.

FAQs

When Should a Buyer Send a Peptide CDMO RFI?

Send the RFI after your team can define the intended market, development stage, target quantity, peptide features, quality requirements, and required filing support. A one-page technical brief produces comparable answers because every candidate responds to the same scope.

How Many Peptide CDMOs Should a Buyer Audit?

Our rule of thumb is to audit 2 or 3 candidates after the paper scorecard identifies clear leaders. More audits consume time without improving the decision when every candidate has the same evidence gap.

Can a Type II DMF Replace a Site Audit?

No. A Type II DMF can support an application by reference, but it does not replace the sponsor’s evaluation of the manufacturing and quality system. FDA reviews DMF content only with a referenced application, and the sponsor still needs site-specific qualification evidence. FDA DMF process

Who Should Approve a Peptide Manufacturing Change?

The sponsor’s QA and CMC owners should approve changes that affect process, equipment, test methods, specifications, materials, sites, or other agreed requirements. ICH Q7 states that contractual changes require the contract giver to be informed and approve them. ICH Q7 change control

At Aarise Pharma, we support peptide API buyers with batch documentation, including COA and MSDS, and describe HPLC and mass-spectrometry testing for peptide batches. Explore our peptide API supply after you have defined the molecule, required documentation, quantity, and supply path.